Omar Arnaout

Omar Arnaout

Auto-generated profile, based on publicly available information

Omar Arnaout

Brigham and Women’s Hospital, Harvard Medical School

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in World Neurosurgery
Verified
Journal Article
Closed access
JSJoeky T. Senders
Joeky T. Senders
PSPatrick C. Staples
Patrick C. Staples
AKAditya V. Karhade
Aditya V. Karhade
MZMark M. Zaki
Mark M. Zaki
WGWilliam B. Gormley
William B. Gormley
OAOmar Arnaout
Omar Arnaout

13 November 2017 in Acta Neurochirurgica
Verified
Journal Article
Closed access
PDF file
JSJoeky T. Senders
Joeky T. Senders
MZMark M. Zaki
Mark M. Zaki
AKAditya V. Karhade
Aditya V. Karhade
BCBliss Chang
Bliss Chang
WGWilliam B. Gormley
William B. Gormley
OAOmar Arnaout
Omar Arnaout

1 April 2011 in Neurosurgery
Verified
Journal Article
Open access
PDF file
MPMartin H Pham
Martin H Pham
RRRudy J. Rahme
Rudy J. Rahme
OAOmar Arnaout
Omar Arnaout
MHMichael C. Hurley
Michael C. Hurley
RBRichard A Bernstein
Richard A Bernstein
BBBernard R. Bendok
Bernard R. Bendok
BACKGROUND:. Carotid and vertebral artery dissections are a leading cause of stroke in young individuals.OBJECTIVE:. To examine the published safety a

1 May 2009 in Neurosurgical Focus
Verified
Journal Article
Closed access
OAOmar M. Arnaout
Omar M. Arnaout
BGBradley A. Gross
Bradley A. Gross
CEChristopher S. Eddleman
Christopher S. Eddleman
BBBernard R. Bendok
Bernard R. Bendok
CGChristopher C. Getch
Christopher C. Getch
HBH. Hunt Batjer
H. Hunt Batjer
Arteriovenous malformations (AVMs) of the posterior fossa are complex neurovascular lesions that are less common than their supratentorial counterparts, accounting for < 15% of all AVMs. The majority of patients with these lesions present with intracranial hemorrhage, a factor that has been consistently shown to increase one's risk for subsequent bleeding. Studies have additionally shown a posterior fossa or deep AVM location to portend a more aggressive natural history. The authors reviewed the literature on posterior fossa AVMs, finding their annual rupture rates to be as high as 11.6%, an important factor that underscores the importance of aggressive treatment of lesions amenable to intervention as therapeutic options and results continue to improve.

1 June 2011 in Neurosurgical Focus
Verified
Journal Article
Closed access
DWDavid G. Weinberg
David G. Weinberg
OAOmar M. Arnaout
Omar M. Arnaout
RRRudy J. Rahme
Rudy J. Rahme
SASalah G. Aoun
Salah G. Aoun
HBH. Hunt Batjer
H. Hunt Batjer
BBBernard R. Bendok
Bernard R. Bendok
Object: Moyamoya disease (MMD) is a rare cerebrovascular disorder involving stenosis of the major vessels of the circle of Willis and proximal portions of its principal branches. Despite concerted investigation, the pathophysiology of the disorder has not been fully elucidated. Currently, the major proteins believed to play an active role in the pathogenesis include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), transforming growth factor–β 1 (TGFβ 1 ), and granulocyte colony-stimulating factor (G-CSF). In terms of the genetics, recent literature suggests a low penetrance autosomal dominant or polygenic mode of transmission involving chromosomes 3, 6, 8, 12, and 17 for familial MMD. This review summarizes the current knowledge on the histopathology, pathophysiology and genetics of MMD. Methods: A PubMed/Medline systematic study of the literature was performed, from which 45 articles regarding MMD pathophysiology were identified and analyzed. Conclusions: Moyamoya disease is characterized by the intimal thickening and media attenuation of the proximal vessels of the circle of Willis as well as the development of an aberrant distal vascular network. The primary proteins that are currently implicated in the pathophysiology of MMD include VEGF, bFGF, HGF, TGFβ 1 , and G-CSF. Furthermore, the current literature on familial MMD has pointed to a low penetrance autosomal dominant or polygenic mode of transmittance at loci on chromosomes 3, 6, 8, 12, and 17.

Verified
Journal Article
Open access
PDF file
CCChristopher Chang
Christopher Chang
VCVelina S. Chavarro
Velina S. Chavarro
JGJakob Gerstl
Jakob Gerstl
SBSarah E Blitz
Sarah E Blitz
LSLennard Spanehl
Lennard Spanehl
JBJoshua Bernstock
Joshua Bernstock
Glioblastoma is the most common and lethal central nervous system malignancy with a median survival after progression of only 6–9 months. Major biochemical mechanisms implicated in glioblastoma recurrence include aberrant molecular pathways, a recurrence-inducing tumor microenvironment, and epigenetic modifications. Contemporary standard-of-care (surgery, radiation, chemotherapy, and tumor treating fields) helps to control the primary tumor but rarely prevents relapse. Cytoreductive treatment such as surgery has shown benefits in recurrent glioblastoma; however, its use remains controversial. Several innovative treatments are emerging for recurrent glioblastoma, including checkpoint inhibitors, chimeric antigen receptor T cell therapy, oncolytic virotherapy, nanoparticle delivery, laser interstitial thermal therapy, and photodynamic therapy. This review seeks to provide readers with an overview of (1) recent discoveries in the molecular basis of recurrence; (2) the role of surgery in treating recurrence; and (3) novel treatment paradigms emerging for recurrent glioblastoma.